AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34179977 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg of OZ439 combined with 450 mg of DSM265
Number of subjects: 0
Study 34179977 — intervention group
Group type: COMPARATOR
Intervention: OZ439 and DSM265 alone (three trials)
Number of subjects: 0
Study 34179977 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of OZ439 and DSM265 (one trial)
Number of subjects: 0
Study 34180037 — intervention group
Group type: EXPERIMENTAL
Intervention: Idasanutlin (QD × 5)
Number of subjects: 85
Study 34180037 — intervention group
Group type: EXPERIMENTAL
Intervention: Idasanutlin (QW × 3)
Number of subjects: 85
Study 34180037 — intervention group
Group type: EXPERIMENTAL
Intervention: Idasanutlin (QD × 3)
Number of subjects: 85
Study 34180037 — intervention group
Group type: EXPERIMENTAL
Intervention: Idasanutlin (all regimens)
Number of subjects: 85
Study 34180037 — intervention group
Group type: EXPERIMENTAL
Intervention: Idasanutlin (QD dosing)
Number of subjects: 85
Study 34180037 — intervention group
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Number of subjects: 85
Study 34180161 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 17418
Study 34180161 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 17418
Study 34180161 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 17418
Study 34180161 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ADHD medications
Number of subjects: 17418
Study 34180331 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib, dexamethasone, and daratumumab (KdD)
Number of subjects: 0
Study 34180331 — intervention group
Group type: COMPARATOR
Intervention: Carfilzomib and dexamethasone (Kd)
Number of subjects: 0
Study 34180691 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit expectations from therapist measured by lexical decision task
Number of subjects: 308
Study 34180691 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit expectations from therapist
Number of subjects: 308
Study 34180691 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist becoming an attachment figure
Number of subjects: 308
Study 34181190 — intervention group
Group type: EXPERIMENTAL
Intervention: Shear Wave Elastography (SWE)
Number of subjects: 46
Study 34181190 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric score using maximal WSS and SWE texture analysis
Number of subjects: 46
Study 34181190 — intervention group
Group type: COMPARATOR
Intervention: Wall Shear Stress (WSS)
Number of subjects: 46
Study 34181276 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2)
Number of subjects: 109
Study 34181697 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of fecal IgA antibodies against Cryptosporidium Cp23 sporozoite protein at one year of life
Number of subjects: 392
Study 34181697 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat infections with Cryptosporidium
Number of subjects: 392
Study 34181697 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat infections
Number of subjects: 392
Study 34181872 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody features towards VAR2CSA identified through machine learning techniques
Number of subjects: 77
Study 34181872 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning techniques (elastic net-regularized logistic regression, partial least squares discriminant analysis)
Number of subjects: 77
Study 34182032 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded stent grafts
Number of subjects: 103
Study 34182226 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab consolidation post-autologous stem cell transplantation
Number of subjects: 0
Study 34182931 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional transesophageal echocardiography (3D-TEE)
Number of subjects: 233
Study 34182931 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 233
Study 34183020 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular use of omega-3 fatty acid supplements (n=856)
Number of subjects: 1002
Study 34183020 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular use of cod liver oil (CLO) (n=173)
Number of subjects: 1002
Study 34183020 — intervention group
Group type: COMPARATOR
Intervention: Non-users of omega-3 fatty acid supplements (n=348)
Number of subjects: 1002
Study 34183258 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery of mesenchymal stem/stromal cells (MSCs) to human subjects with RAS
Number of subjects: 0
Study 34183258 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental regenerative approaches involving reparative cells or products
Number of subjects: 0
Study 34183269 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly semaglutide
Number of subjects: 331
Study 34184246 — intervention group
Group type: EXPERIMENTAL
Intervention: Late night removal (between 10 pm to midnight)
Number of subjects: 12241
Study 34184246 — intervention group
Group type: COMPARATOR
Intervention: Early morning removal (between 6 am to 7 am)
Number of subjects: 12241
Study 34184246 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter durations of catheterisation
Number of subjects: 12241
Study 34184246 — intervention group
Group type: EXPERIMENTAL
Intervention: Clamping catheters
Number of subjects: 12241
Study 34184246 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic alpha blockers
Number of subjects: 12241
Study 34184251 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to reduce sedentary behaviour (including physical activity interventions, multicomponent lifestyle interventions, and interventions to interrupt sedentary behaviour)
Number of subjects: 753
Study 34184251 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to reduce sedentary behaviour
Number of subjects: 753
Study 34184326 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated dd-cfDNA (≥1%)
Number of subjects: 0
Study 34184326 — intervention group
Group type: EXPERIMENTAL
Intervention: dd-cfDNA variability (≥.34%)
Number of subjects: 0
Study 34184326 — intervention group
Group type: EXPERIMENTAL
Intervention: Samples from patients with concurrent de novo HLA DSAs
Number of subjects: 0
Study 34184441 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan-based antihypertensive therapy
Number of subjects: 1035
Study 34184659 — intervention group
Group type: EXPERIMENTAL
Intervention: Overinvestment
Number of subjects: 1774
Study 34184659 — intervention group
Group type: EXPERIMENTAL
Intervention: Job Demand Control Support and Effort-Reward Imbalance models
Number of subjects: 1774
Study 34184935 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic CT
Number of subjects: 10735
Study 34184935 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of pneumonia at CT
Number of subjects: 10735
Study 34184935 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical variables score
Number of subjects: 10735
Study 34184935 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical variables score + extent of pneumonia and coronary calcium score at CT
Number of subjects: 10735
Study 34185002 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized dietary advice
Number of subjects: 37
Study 34185020 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional medication adherence program (IMAP) with regular motivational interviewing sessions and delivery of PKIs in electronic monitors
Number of subjects: 262
Study 34185020 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional medication adherence program (IMAP)
Number of subjects: 262
Study 34185020 — intervention group
Group type: EXPERIMENTAL
Intervention: PKI pharmacokinetics
Number of subjects: 262
Study 34185020 — intervention group
Group type: EXPERIMENTAL
Intervention: PKI dosage adaptation
Number of subjects: 262
Study 34185022 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive life-simulation game
Number of subjects: 300
Study 34185022 — intervention group
Group type: COMPARATOR
Intervention: App-based HIV educational materials
Number of subjects: 300
Study 34185084 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Electrical Neuromodulation (REN)
Number of subjects: 35
Study 34185084 — intervention group
Group type: COMPARATOR
Intervention: Standard-care medications (triptans or over-the-counter medications)
Number of subjects: 35
Study 34185220 — intervention group
Group type: EXPERIMENTAL
Intervention: CHD survivors
Number of subjects: 744
Study 34185220 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 744
Study 34185220 — intervention group
Group type: EXPERIMENTAL
Intervention: CHD survivors with severe functional limitations
Number of subjects: 744
Study 34185220 — intervention group
Group type: EXPERIMENTAL
Intervention: CHD care in the Midwest
Number of subjects: 744
Study 34185220 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness perception dimensions (Concern and Emotional Response)
Number of subjects: 744
Study 34185611 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34185708 — intervention group
Group type: EXPERIMENTAL
Intervention: Dantrolene sodium
Number of subjects: 0
Study 34185827 — intervention group
Group type: EXPERIMENTAL
Intervention: HFRS (Hospital Frailty Risk Score)
Number of subjects: 1042234
Study 34185838 — intervention group
Group type: EXPERIMENTAL
Intervention: ART initiated <48 hours after birth
Number of subjects: 63
Study 34185838 — intervention group
Group type: EXPERIMENTAL
Intervention: ART initiated <14 days after birth
Number of subjects: 63
Study 34185838 — intervention group
Group type: EXPERIMENTAL
Intervention: ART initiated >14 days after birth
Number of subjects: 63
Study 34185838 — intervention group
Group type: EXPERIMENTAL
Intervention: No antenatal maternal ART
Number of subjects: 63
Study 34185838 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 63
Study 34185953 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab (9 μg/day for week 1, 28 μg/day for weeks 2-4, followed by 2 weeks of no treatment; 28 μg/day in subsequent cycles)
Number of subjects: 45
Study 34185953 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 45
Study 34186052 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use duodenoscope by expert endoscopists
Number of subjects: 200
Study 34186052 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use duodenoscope by less-expert endoscopists
Number of subjects: 200
Study 34186052 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedures of high complexity (grades 3-4)
Number of subjects: 200
Study 34186052 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 200
Study 34186262 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/ledipasvir (SOF/LED)
Number of subjects: 26
Study 34186262 — intervention group
Group type: EXPERIMENTAL
Intervention: Total bilirubin ≥1.93 mg/dL
Number of subjects: 26
Study 34187182 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural plasma levels of MRproANP (midregional N-terminal pro-atrial natriuretic peptide)
Number of subjects: 106
Study 34187182 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural plasma levels of sST2 (soluble suppression of tumorigenicity 2)
Number of subjects: 106
Study 34187182 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation for atrial fibrillation
Number of subjects: 106
Study 34187187 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 93
Study 34187401 — intervention group
Group type: EXPERIMENTAL
Intervention: Copanlisib (60 mg intravenous on days 1, 8, 15 for 6 cycles of 28 days) and Rituximab (375 mg/m2)
Number of subjects: 0
Study 34187516 — intervention group
Group type: EXPERIMENTAL
Intervention: Dercum's disease (DD)
Number of subjects: 46
Study 34187516 — intervention group
Group type: EXPERIMENTAL
Intervention: Roch-Leri mesosomatic lipomatosis (LMS)
Number of subjects: 46
Study 34187516 — intervention group
Group type: COMPARATOR
Intervention: Lean controls
Number of subjects: 46
Study 34187516 — intervention group
Group type: COMPARATOR
Intervention: Obese controls
Number of subjects: 46
Study 34187614 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pandemic lifetime mental disorders
Number of subjects: 3500
Study 34187614 — intervention group
Group type: EXPERIMENTAL
Intervention: Current mental disorders
Number of subjects: 3500
Study 34187614 — intervention group
Group type: EXPERIMENTAL
Intervention: Major depressive disorder
Number of subjects: 3500
Study 34187614 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalised anxiety disorder
Number of subjects: 3500
Study 34187614 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-traumatic stress disorder
Number of subjects: 3500
Study 34187614 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic attacks
Number of subjects: 3500
Study 34187614 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol/substance use disorder
Number of subjects: 3500
Study 34187614 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic-related adverse events-experiences
Number of subjects: 3500
Study 34187614 — intervention group
Group type: EXPERIMENTAL
Intervention: Having loved ones infected with COVID-19
Number of subjects: 3500
Study 34187698 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of malnutrition (MN)
Number of subjects: 205
Study 34187698 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of oropharyngeal dysphagia (OD)
Number of subjects: 205
Study 34187739 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies (mAbs) against immune checkpoints (ICIs)
Number of subjects: 0
Study 34187739 — intervention group
Group type: EXPERIMENTAL
Intervention: Druggable strategies modulating PD-L1 expression
Number of subjects: 0
Study 34187821 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support system for FQ PPA integrated into EHRs
Number of subjects: 12
Study 34187831 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities of Daily Living (ADL) measured by modified Rankin Scale scores
Number of subjects: 300
Study 34187831 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Rated Health (SRH)
Number of subjects: 300
Study 34187831 — intervention group
Group type: EXPERIMENTAL
Intervention: Further measures of ADL, functional health, physical activity, falls and fatigue
Number of subjects: 300
Study 34187831 — intervention group
Group type: EXPERIMENTAL
Intervention: Views on ageing, social support, resilience-related concepts, affect, frailty, illness perceptions and loneliness
Number of subjects: 300
Study 34187841 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia (n = 28)
Number of subjects: 76
Study 34187841 — intervention group
Group type: COMPARATOR
Intervention: Normoglycemia (n = 48)
Number of subjects: 76
Study 34187851 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant PD-1 inhibition (2 cycles)
Number of subjects: 20
Study 34187867 — intervention group
Group type: EXPERIMENTAL
Intervention: NfL plasma concentrations in AD patients
Number of subjects: 865
Study 34187867 — intervention group
Group type: EXPERIMENTAL
Intervention: p-tau181 plasma concentrations in AD patients
Number of subjects: 865
Study 34187867 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline concentrations of p-tau181 and NfL
Number of subjects: 865
Study 34187867 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of change of NfL
Number of subjects: 865
Study 34187867 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive performance
Number of subjects: 865
Study 34187871 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) with concurrent intravenous (IV) alteplase
Number of subjects: 0
Study 34187871 — intervention group
Group type: COMPARATOR
Intervention: Endovascular treatment (EVT) only
Number of subjects: 0
Study 34187993 — intervention group
Group type: EXPERIMENTAL
Intervention: HEAR score <2
Number of subjects: 1402
Study 34187993 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step HEART strategy
Number of subjects: 1402
Study 34188166 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PTX3 above 4.34 ng/mL
Number of subjects: 0
Study 34188166 — intervention group
Group type: COMPARATOR
Intervention: Serum CA19-9 and CEA
Number of subjects: 0
Study 34188166 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans-retinoic acid (ATRA)
Number of subjects: 0
Study 34188166 — intervention group
Group type: EXPERIMENTAL
Intervention: Stromal modulation by ATRA
Number of subjects: 0
Study 34188166 — intervention group
Group type: COMPARATOR
Intervention: SCALOP clinical trial (chemo-radiotherapy without stromal targeting)
Number of subjects: 0
Study 34188166 — intervention group
Group type: EXPERIMENTAL
Intervention: STARPAC clinical trial (NCT03307148)
Number of subjects: 0
Study 34188440 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV with ILM peeling
Number of subjects: 10
Study 34188580 — intervention group
Group type: EXPERIMENTAL
Intervention: pdVWF/FVIII (VONCENTO)
Number of subjects: 35
Study 34189178 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg) with loperamide
Number of subjects: 119
Study 34189178 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg) with loperamide
Number of subjects: 119
Study 34189178 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (1650 mg) with loperamide
Number of subjects: 119
Study 34189178 — intervention group
Group type: COMPARATOR
Intervention: Control (pre-antibiotic treatment)
Number of subjects: 119
Study 34189463 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 5 mg/kg every 2 weeks for 12 weeks
Number of subjects: 2
Study 34189463 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment
Number of subjects: 2
Study 34189463 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab therapy
Number of subjects: 2
Study 34190375 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (SUN) plus Evofosfamide (EVO) 340 mg/m
Number of subjects: 17
Study 34190375 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (SUN) plus Evofosfamide (EVO)
Number of subjects: 17
Study 34190592 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartLogic algorithm activated in patients
Number of subjects: 366
Study 34190592 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical actions taken in response to HeartLogic alerts
Number of subjects: 366
Study 34190592 — intervention group
Group type: COMPARATOR
Intervention: Extra in-office visits for managing HeartLogic alerts
Number of subjects: 366
Study 34190999 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted messaging
Number of subjects: 0
Study 34190999 — intervention group
Group type: COMPARATOR
Intervention: Control group (no targeted messaging)
Number of subjects: 0
Study 34191021 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain kale
Number of subjects: 106
Study 34191021 — intervention group
Group type: EXPERIMENTAL
Intervention: Kale with 1.2% added sugar
Number of subjects: 106
Study 34191021 — intervention group
Group type: EXPERIMENTAL
Intervention: Kale with 1.8% added sugar
Number of subjects: 106
Study 34191021 — intervention group
Group type: EXPERIMENTAL
Intervention: Kale with 0.2% added salt
Number of subjects: 106
Study 34191021 — intervention group
Group type: EXPERIMENTAL
Intervention: Older infants (≥18 mo)
Number of subjects: 106
Study 34191021 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding history
Number of subjects: 106
Study 34191195 — intervention group
Group type: EXPERIMENTAL
Intervention: FLT-PET/DW-MRI
Number of subjects: 12
Study 34191195 — intervention group
Group type: EXPERIMENTAL
Intervention: FLT-PET
Number of subjects: 12
Study 34191195 — intervention group
Group type: COMPARATOR
Intervention: FDG-PET/CT
Number of subjects: 12
Study 34191201 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane- or platinum-based chemotherapy
Number of subjects: 116
Study 34191621 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) at 225 mg twice daily
Number of subjects: 138
Study 34192154 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 antibody testing using chemiluminescence assays (chemiluminescence immunoassay and electrochemiluminescence)
Number of subjects: 318
Study 34192154 — intervention group
Group type: COMPARATOR
Intervention: ELISA and POC testing
Number of subjects: 318
Study 34192154 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral antibody titres
Number of subjects: 318
Study 34192154 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing methods
Number of subjects: 318
Study 34192239 — intervention group
Group type: EXPERIMENTAL
Intervention: Chatbot users for breast cancer, asthma, depression, and migraine
Number of subjects: 1771
Study 34192953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac screening including ECG, echocardiography, and 24-hour Holter monitoring
Number of subjects: 145
Study 34192989 — intervention group
Group type: EXPERIMENTAL
Intervention: LBSA0103 hyaluronic acid injection
Number of subjects: 1949
Study 34193084 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic prediction model for falls rate
Number of subjects: 198
Study 34193096 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention consisting of a 20-25 min oral presentation in Urdu and Somali on cervical cancer and screening.
Number of subjects: 0
Study 34193096 — intervention group
Group type: COMPARATOR
Intervention: Control group (women from Pakistan and Somalia residing in Oslo).
Number of subjects: 0
Study 34193096 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention (I).
Number of subjects: 0
Study 34193138 — intervention group
Group type: EXPERIMENTAL
Intervention: Routinised syphilis testing alongside regular viral load bloodwork
Number of subjects: 21
Study 34193138 — intervention group
Group type: EXPERIMENTAL
Intervention: Routinised syphilis testing
Number of subjects: 21
Study 34193138 — intervention group
Group type: EXPERIMENTAL
Intervention: Opting out of testing based on self-assessment of syphilis risk
Number of subjects: 21
Study 34193140 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model predicting presence of immune-related adverse events (irAEs) using ePRO data.
Number of subjects: 34
Study 34193140 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model predicting onset of immune-related adverse events (irAEs) using ePRO data.
Number of subjects: 34
Study 34193171 — intervention group
Group type: EXPERIMENTAL
Intervention: Image fusion system (n=5)
Number of subjects: 10
Study 34193171 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=5)
Number of subjects: 10